Effect of Angiotensin Converting Enzyme Inhibitor on Collagen Production by Cultured Mesangial Cells

Article information

Korean J Intern Med. 1994;9(1):9-13
Department of Internal Medicine, Kyunghee University College of Medicine, Seoul, Korea
Address reprint requests to: Chun-Gyoo Ihm, M.D., Division of Nephrology, Department of Internal Medicine, Kyunghee University Medical Center, #1 Hoiki-Dong, Dongdaemum-Ku, Seoul, 130-702, Korea, Phone (02) 966-5191 (ext. 2319). FAX (02) 968-1848

Abstract

Cultured mesangial cells (MC) express renin mRNA and generate angiotensin I, supporting the action of local renin-angiotensin system. Also angiotensin II may act like a growth factor and was reported to increase collagen production (CP) in cultured MC. Angiotensin converting enzyme inhibitor is suggested to attenuate development and advancement of glomerulosclerosis, mainly with its hemodynamic effects. Therefore, we investigated the direct effects of enalapril (E) on CP by cultured MC. Rat MC were cultured in DMEM media alone, or containing high glucose (HG: 25 mM) or soluble immune complex (IC) prepared with bovine gamma globulin (BGG) and anti-BGG, with or without E (0.2 ug/ml). CP was determined after 24 h by [3H] proline incorporation method. E significantly reduced CP by 43% in medium as compared with control (C)(C: 37,210±4,200 vs C+E: 21,350 ± 5,080 cpm/well, p<0.01). CP in medium increased in the presence of HG (123% of C) or IC (147% of C), which was, however, prevented with E (HG + E: 105% of C, IC+E: 116% of C). There were no differences of CP in cell layer between C (3,490±220 cpm/well) and C+E (3,340±190 cpm/well), and also no changes after, addition of E in HG or IC groups. In conclusion, E directly attenuates CP by MC, even in the presence of HG or IC, independently of its hemodynamic effects.

INTRODUCTION

It’s recently been suggested that the glomerular mesangial expansion may be the common pathway into the development of glomerulosclerosis in several glomerular diseases, such as immunemediated glomerulonephritis and diabetic nephropathy1,2). It’s reported to be due to the synthesis and accumulation of extracellular matrix proteins (ECM) such as collagen39).

Since the methods of mesangial cell culture were established10), the mesangial cells (MC) have been observed to proliferate or produce ECM in response to injurious stimuli2,3,10) and also to secrete biologically active substances such as cytokine growth factors as effectors cells1116). Especially, it’s interesting to determine whether high glucose or immune complex (IC) could exert any effects on MC3,1720).

MC were reported to express renin-like enzyme activity and generate angiotensin I21,22). Angiotensin II was observed to increase collagen production in cultured MC23) and, therefore, may act as a growth factor. Also, angiotensin converting enzyme (ACE) inhibitor has been suggested to attenuate glomerulosclerosis, probably mainly through its hemodynamic effect2427), which remain controversial with recent studies2830).

Therefore, the direct effect of ACE inhibitor, enalapril, on MC were investigated from the aspects of collagen production or DNA synthesis. Also, It was examined whether soluble IC or high glucose exert any effects on cultured MC, and these changes are modulated by enalapril in vitro.

METHODS

Isolation and identification of rat glomerular MC: Glomeruli were isolated from Sprague-Dawley rats using techniques previously described10,14). Collagenase (GIBCO Laboratories, Grand Island, NY, USA)-treated glomeruli were plated on culture dishes in DMEM media containing 17% heat-inactivated fetal bovine serum (FBS), glutamine, penicillin, streptomycin, amphotericin and insulin. Near confluent cells in third to fourth passage were used in these studies. The cells have prominent intracellular myosin fibrils and were negative with antibodies (Becton Dickinson, Mountain View, CA, USA) to common leukocyte antigen and factor VIII by immunofluorescent staining. The cells were capable of growth in D-valine substituted medium and were not sensitive to puromycin.

Experimental groups: the medium was replaced according to the experimental design shown as follows. 1) Control, 2) Enalapril group; enalapril 0.2ug/ml, 3) IC prepared with bovine γ-globulin (BGG) and rabbit IgG anti-BGG at five times excess antigen as previously described17), 4) IC+enalapril group, 5) High glucose; 25 mM glucose, 6) High glucose+enalapril group.

Collagen and non-collagen protein production: De novo collagen synthesis was measured by the incorporation of {3H} proline into collagenase-digestible material as described31). MC were plated at 1×105 cells per well in 6-welll plates in basal medium supplemented with 17% FBS and 5.6 mM (100 mg/dl) glucose. After 72 hr of starvation with serum-free medium, the medium was again changed to medium with 0.2% FBS, 5.6 mM (100 mg/dl) glucose, 50 μg each of sodium ascorbate and β-aminopropionitrile, and the indicated amount of various materials according to the experimental design as mentioned above. The cells were labeled with 5μCi of {3H} proline (Amersham Corp., Arlington Heights, IL, USA). After 24 hr incubation, the proteins in cell and medium were precipitated with 2 ml of 10% TCA and 1% tannic acid. The washed precipitates were dissolved in 0.1 N NaOH and neutralized, and the solubilized proteins were digested with 100 units of highly purified collagenase (GIBCO) in 0.1 M Tris-buffer (pH = 7.6) containing 10 mM CaC12 and 20 mM N-ethyl maleimide for 1 hr at 37°C. Collagenase digestible protein and non-collagenous protein were separated with TCA and tannic acid and the radioactivity of each fraction was determined.

Thymidine incorporation assays: Cells were plated at 1×104 cells per well 96-well plates in DMEM medium containing 17% FBS. One μCi per well of {3H} thymidine (New England Nuclear, Boston, Massachusetts, USA) was added after the medium was replaced according to the experimental design. After 16 hr incubation, the contents of each well were counted in a liquid scintillation counter32).

Statistical Analysis

The results are expressed as mean ± SEM. Statistical evaluation of the data was performed using a Student’s test and ANOVA. Probability values <0.05 were considered significant.

RESULTS

Collagen production in medium by MC in Enalapril group was significantly lower than Control for the first 24 hours and was 57% of control (Enalapril group: 21,350±5,080 vs Control: 37,210±4,200 cpm/well, n = 6, p<0.01) (Table 1, Fig. 1). No differences of non-collagen production in medium were noticed between the two groups. Therefore, the ratio of collagen/total protein production was lower in Enalapril group than in Control. However, there were no differences of collagen production in cell layer between Control (3,490±220) cpm/well) and Enalapril group (3,340±190 cpm/well).

Effects of Enalapril on Collagen Production by Mesangial Cells       (cpm/well, mean±SD)

Fig. 1.

Collagen production in medium by mesangial cells (Mean ± SD) was significantly reduced by enalapril (*p<0.01 vs control).

Collagen production in medium was significantly higher in the presence of IC or High glucose (147% and 123% of Control, respectively) than in Control (p<0.05) (Fig. 2). But, IC or high glucose-induced increases in collagen production were significantly prevented with the addition of enalapril (116% and 105% of Control, respectively, p<0.05).

Fig. 2.

The immune complex or high glucose-induced increases in collagen production in medium were prevented by enalapril (% of mean control value). C: control, IC: immune complex, HG: high glucose, E: enalapril. *p<0.05 IC vs C or IC + E, HG vs C or HG + E **p<0.05 IC + E vs C

When cultured in soluble IC or high glucose, the thymidine incorporation of mesangial cells was decreased as compared with control (63.5% and 72.6% of control, respectively, p<0.05) (Table 3). The addition of enalapril, however, exerted no effects on these changes in IC or High glucose groups.

Effects of Enalapril on Thymidine Incorporation Induced by Immune Complex or High Glucose

DISCUSSION

According to these experiments, ACE inhibitor, enalapril, could directly reduce collagen production by MC in vitro. This supports the recent studies that ACE inhibitor could prevent the progression of renal disease in the absence of hemodynamic effects. Also, it suggests that there is the local renin-angiotensin system in cultured MC which enalapril could inhibit.

It has been demonstrated that angiotensin II as a growth factor can induce cellular hypertrophy and also proliferation in MC23,3335). Angiotensin II directly stimulates the synthesis of extracellular matrix proteins, mainly type I collagen23). Also angiotensin II was observed to induce the synthesis of interleukin-636) and platelet activating factor37) in MC, offering multiple possibilities for the regulation of autocrine and/or paracrine effects of this peptide. Therefore, it’s also possible that the effects of angiotensin II to stimulate collagen production may, in part at least, be mediated by these growth factors. Recently, AT1-angiotensin II receptor was observed to be expressed in MC of human and animals38,39). Current evidences suggest that the AT1 receptor is coupled via G proteins to traditional signal transduction mechanisms such as stimulation of phospholipase C, calcium mobilization and inhibition of adenylate cyclase40).

On the other hand, high glucose induced increases in collagen production by MC in these experiments, as previously reported19,20). High glucose may activate the polyol pathway increasing the glycosylation of proteins by nonenzymatic means, or stimulate second messenger pathways resulting in alterations in the synthesis or degradation of extracellular matrix proteins41). Also, IC stimulated collagen production by MC in these experiments. Soluble IC was previously observed to bind to cultured MC through FC receptor and to activate MC17). While high glucose was related to transforming growth factor-β42), IC were also reported to stimulate the synthesis of interleukin-1 and −618,43). All of these factors could induce the synthesis of extracellular matrix proteins44,45). Therefore, our study complements the reports that collagen synthesis and accumulation leading to mesangial expansion and/or late glomerulosclerosis was increased in IC-mediated glomerulonephritis or diabetic nephropathy models4,5,9,46). According to these experiments, enalapril can reduce the increase in collagen production induced by IC and high glucose. While the underlying mechanisms remain to be delineated, it may be through the inhibition of generation of angiotensin II and related to the above pathways or interaction with growth factors.

When cultured in soluble IC or high glucose in these experiments, the thymidine uptake by MC was decreased, and the addition of enalapril, however, exerted no effects on these changes. The proliferate effects of angiotensin II have not been confirmed by all investigators33).

In conclusion, ACE inhibitor, enalapril, could directly reduce collagen production by MC, also induced by IC or high glucose, irrespective of its hemodynamic effects. Further studies are necessary to investigate the intracellular mechanisms on the levels of collagen gene expression and the interaction of some sutocrine growth factors by using this culture model.

Effect of Enalapril on Non-Collagen Production Mesangial Cells        (cpm/well, Mean ± SD)

Acknowledgements

This study was supported by the Chong-Ram grant in 1990 from the Korean Association of Internal Medicine

References

1. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC. Structural functional relationships in diabetic nephropathy. J Clin Invest 74:1143. 1984;
2. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 318:1657. 1988;
3. Ayo SH, Rodnik RA, Garoni J, Glass WF II, Kreiberg JI. High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am J Pathol 136:1339. 1990;
4. Falk RJ, Scheinman JI, Mauer SM, Michael AF. Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. Diabetes 32(Suppl 2):34. 1983;
5. Floege J, Hohnson RJ, Gordon K, Lida H, Pritzl P, Yoshimura A, Campbell Alpers CE, Couser WG. Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int 40:477. 1991;
6. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 86:453. 1990;
7. Goyal M, Wiggins R. Fibronectin mRNA and protein accumulation, distribution, and breakdown in rabbit anti-glomerular basement membrane disease. J Am Soc Nephrol 1:1334. 1991;
8. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H. Effects of methylprednisolone on glomerular and medullary mRNA levels for extracellular matrices in puromycin aminonucleoside nephrosis. Kidney Int 40:874. 1991;
9. Striker LM, Killen PD, Chi E, Striker GE. The composition of glomerulosclerosis. I. studies in focal sclerosis, crescentic glomerulonephritis, and membranoproliferative glomerulonephritis. Lab Invest 51:181. 1984;
10. Striker GE, Striker LJ. Glomerular cell culture. Lab Invest 53:122. 1985;
11. Shultz PA, Dicorleto PE, Silver BJ, Abboud HE. Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am J Physiol 255:F674. 1988;
12. Joza C, Benigni A, Renzi D, Piccinelli A, Perico N, Remuzzi G. Endothelin and eicosanoid synthesis in cultured mesangial cells. Kidney Int 37:927. 1990;
13. Ruef C, Budde K, Lacy J, Northemann W, Baumann M, Sterzel RB, Coleman DL. Interleukin 6 is an autocrine factor for mesangial cells. Kidney Int 38:249. 1990;
14. Lovett DH, Szamel M, Ryan JL, Sterzel RB, Gemsa D, Resch K. Interleukin 1 and the glomerular mesangium; I. Purification and characterization of a mesangial cell-derived autogrowth factor. J Immunol 136:3700. 1986;
15. Conti GF, Striker LJ, Elliot SJ, Andreani D, Striker GE. Synthesis and release of insulinlike growth factor I by mesangial cells in culture. Am J Physiol 255:F1214. 1988;
16. Werber HI, Emancipator SN, Tykocinski ML, Sedor JR. The IL-1 gene is expressed by rat glomerular mesangial cells and is augmented in immune complex glomerulonephritis. J Immunol 138:3107. 1987;
17. Sedor JR, Carey SW, Emancipator SN. Immune complexes bind to cultured rat glomerular mesangial cells to stimulate superoxide release. J Immunol 138:3751. 1987;
18. Matsumoto K, Hatano M. Soluble immune complexes stimulate production of interleukin-1 by cultured rat glomerular mesangial cells. Am J Nephrol 11:138. 1991;
19. Bernstein J, Cheng F, Roszka J. Increased glucose increases glomerular basement membrane in metanephric culture. Pediatr Nephrol 1:3. 1987;
20. Ihm CG, Park JK, Ahn JH, Lee TW, Kim MJ. Effects of glucose, insulin and somatostatin on collagen production by glomerular mesangial cells. Korean J of Nephrol 11:200. 1992;
21. Chansel D, Dussaule J-C, Ardillou N, Ardaillou R. Identification and regulation of renin in human cultured mesagial cells. Am J Pjysiol 252:F32. 1987;
22. Dzau VJ, Kreisberg JI. Cultured glomerular mesangial cells contain renin: influence of calcium and isoproterenol. J Cardiovasc Pharmacol 8(Suppl):1o:S6. 1986;
23. Wolf G, Haberstroh U, Heilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 140:95. 1992;
24. Navar IG, Rosivall L. Contribution of the reninangiotensin system to the control of intrarenal hemodynamics. Kidney Int 25:857. 1984;
25. Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM. Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 55:669. 1984;
26. Pelayo JC, Quan Ah, Shanley PF. Angiotensin II control of the renal microcirculation in rats with reduced renal mass. Am J Physil 258:F414. 1990;
27. Kastner PR, Hall JE, Guyton AC. Control of glomerular filtration rate: Role of intrarenally formed angiotensin II. Am J Physiol 246:F414. 1990;
28. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993. 1986;
29. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesion. Kidney Int 40:195. 1991;
30. Wight JP, Bassett AH, Le Carpentier JE. E1 Nahas AM: Effect of treatment with enalapril, verapamil and indomethacin on compensatory renal growth in the rat. Nephrol Dial Transplant 5:777. 1990;
31. Hakeda Y, Nakatani Y, Kurihara N, Ikeda E, Maeda N, Kumegawa M. Prostaglandin E2 stimulates collagen and non-collagen protein synthesis and prolyl hydroxylase activity in osteoblastic clone MC3T3-E1 cells. Biochem Biophys Res Comm 126:340. 1985;
32. MacKay K, Striker LJ, Stauffer JW, Doi T, Agodoa LY, Striker GE. Transforming growth factor-β. J Clin Invest 83:1160. 1989;
33. Homma T, Hoover RL, Ichikawa I, Harris RC. Angiotensin II induces hypertrophy and stimulates collagen production in cultured rat glomerular mesangial cells [Abstract]. Clin Res 38:358. 1990;
34. Anderson PW, Do YS, Hsueh WA. Angiotensin II causes mesangial cell hypertrophy (Abstract). Hypertension 18:382. 1991;
35. Ray PE, Aguilera G, Kopp JB, Horikoshi S, Klotman PE. Angiotensin II receptor-mediated proliferation of cultured human fetal mesangial cells. Kidney Int 40:764. 1991;
36. Fujibayashi M, Fujiwara Y, Fukunaga M. Vasoconstrictors stimulate interleukin 6 (IL-6) release from mouse mesangial cells (Abstract). J Am Soc Nephrol 2:437. 1991;
37. Neuwirth R, Satriano JA, DeCandido S, Clay K, Schlondorff D. Angiotensin II causes formation of platelet activating factor in cultured rat mesangial cells. Cir Res :1224. 1989;
38. Groene JH, Simon M, Fuchs E. Autoradiographic characterization of angiotensin receptor subtypes in fetal and adult human kidney. Am J Physil 262:F326. 1992;
39. Sechi LA, Grady EF, Griffin CA, Kalinyak JE, Schambelan M. Distribution of angiotensin II receptor subtypes in rat and human kidney. Am J Physiol 262:F236. 1992;
40. Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol 3:1531–1540. 1993;
41. Kreisberg JI. Biology of disease. Hyperglycemia and microangiopathy. Direct regulation by glucose of microvascular cells. Lab Invest 67:416. 1992;
42. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-β. Kidney Int 42:647. 1992;
43. Dobbelsteen MEa, Woude FJ, Schroeijers WEM, Es LA, Daha MR. Souble aggregates of IgG and immune complexes enhance IL-6 production by renal mesangial cells. Kidney Int 43:544. 1993;
44. Border WA, Okuda S, Languino LR, Ruslahti E. Transforming growth factor-β regulates production of proteoglycans by mesangial cells. Kidney Int 37:689. 1990;
45. Torbohm I, Berger B, Schoenermark M, Kempis JV, Rother K, Haensch GM. Modulation of collagen synthesis in human glomerular epithelial cells by interleukin-1. Clin Exp Immunol 75:427. 1989;
46. Ihm CG, Lee GSL, Nast CC, Artishevsky A, Guillermo R, Levin PS, Glassock RJ, Adler SG. Early increased renal procollagen α1(IV) mRNA levels in streptozotocin imduced diabetes. Kidney Int 41:768. 1992;

Article information Continued

Fig. 1.

Collagen production in medium by mesangial cells (Mean ± SD) was significantly reduced by enalapril (*p<0.01 vs control).

Fig. 2.

The immune complex or high glucose-induced increases in collagen production in medium were prevented by enalapril (% of mean control value). C: control, IC: immune complex, HG: high glucose, E: enalapril. *p<0.05 IC vs C or IC + E, HG vs C or HG + E **p<0.05 IC + E vs C

Table 1.

Effects of Enalapril on Collagen Production by Mesangial Cells       (cpm/well, mean±SD)

Medium Cell layer
Control (n = 6) 37,210±4,200 3,490±220
Enalapril (n = 6) 21,350±5,080* 3,340± 190
*

p<0.01 vs Control

Table 2.

Effect of Enalapril on Non-Collagen Production Mesangial Cells        (cpm/well, Mean ± SD)

Medium Cell layer
Control (n = 6) 21,430 ± 2,430 2,780 ± 210
Enalapril (n = 6) 24,140 ± 3,200 2,590 ± 300

Table 3.

Effects of Enalapril on Thymidine Incorporation Induced by Immune Complex or High Glucose

Thymidine incorporation (% of Control)
Without Enalapril With Enalapril
Immune complex (n = 6) 63.5 ± 4.0 68.0 ± 7.9
High glucose (n = 6) 72.6 ± 15.4 70.0 ± 17.2

all are decreased as compared with control (p<0.05)